It is well-known that schizophrenia and related psychotic disorders are a chronic and often disabling condition.
Despite modern treatment techniques they still present an enormous burden to the patients and their relatives and take a serious toll in terms of human suffering and societal expenditure.
The diagnosis of schizophrenia is associated with demonstrable alterations in brain structure and changes in neurotransmission, with increased dopamine action being directly related to typical positive symptoms such as hallucinations and delusions. Negative symptoms include restricted range and intensity of emotional expression, reduced thought and speech, and social withdrawal. In general, schizophrenia presents a bewildering complexity of symptoms in multiple domains in great heterogeneity across individuals and also variability within individuals over time.
Even today psychotic disorders remain highly stigmatised, and despite the young age of the patients and the long-term service dependence often are not prioritised in the agenda of public health.